0001140361-21-029188.txt : 20210823
0001140361-21-029188.hdr.sgml : 20210823
20210823210039
ACCESSION NUMBER: 0001140361-21-029188
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210819
FILED AS OF DATE: 20210823
DATE AS OF CHANGE: 20210823
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SIMON IRWIN D
CENTRAL INDEX KEY: 0000922748
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38594
FILM NUMBER: 211198303
MAIL ADDRESS:
STREET 1: C/O THE HAIN CELESTIAL GROUP INC.
STREET 2: 1111 MARCUS AVENUE
CITY: LAKE SUCCESS
STATE: NY
ZIP: 11042
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tilray, Inc.
CENTRAL INDEX KEY: 0001731348
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 824310622
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 655 MADISON AVENUE
STREET 2: 19TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10065
BUSINESS PHONE: 519.322.8800
MAIL ADDRESS:
STREET 1: 655 MADISON AVENUE
STREET 2: 19TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10065
4
1
form4.xml
FORM 4
X0306
4
2021-08-19
0001731348
Tilray, Inc.
TLRY
0000922748
SIMON IRWIN D
C/O TILRAY, INC.
655 MADISON AVENUE, 19TH FLOOR
NEW YORK
NY
10065
true
true
President and CEO
Class 2 Common Stock
2021-08-19
4
M
0
180251
A
653510
D
Class 2 Common Stock
2021-08-19
4
F
0
89495
12.68
D
564015
D
Class 2 Common Stock
2021-08-19
4
M
0
72683
A
636698
D
Class 2 Common Stock
2021-08-19
4
F
0
36088
12.68
D
600610
D
Class 2 Common Stock
2021-08-19
4
M
0
242277
A
842887
D
Class 2 Common Stock
2021-08-19
4
F
0
120291
12.68
D
722596
D
Restricted Stock Units
2021-08-19
4
M
0
180251
0
D
Class 2 Common Stock
180251
0
D
Restricted Stock Units
2021-08-19
4
M
0
72683
0
D
Class 2 Common Stock
72683
0
D
Restricted Stock Units
2021-08-19
4
M
0
242277
0
D
Class 2 Common Stock
242277
0
D
These shares were retained by Tilray, Inc. ("Tilray") via settlement on a net withholding basis in order to meet the tax withholding obligations of the reporting person in connection with the vesting of installments of restricted stock units ("RSUs") granted to the reporting person on January 22, 2020 and August 12, 2020. None of these shares were sold in an open market transaction.
RSUs convert into shares of Tilray Class 2 Common Stock on a one-for-one basis.
On August 12, 2020, the reporting person was granted 360,502 RSUs, with 50% vesting on August 12, 2021, and the remaining 50% scheduled to vest on August 12, 2022. On August 19, 2021, the Compensation Committee of Tilray's Board of Directors (the "Compensation Committee") accelerated the vesting of the remaining unvested RSUs.
On January 22, 2020, the reporting person was granted 218,038 RSUs, 33.33% of which vested on June 1, 2020; 33.33% of which vested on June 1, 2021; with the remaining 33.34% scheduled to vest on June 1, 2022. On August 19, 2021, the Compensation Committee accelerated the vesting of the remaining unvested RSUs.
On January 22, 2020, the reporting person was granted 726,794 RSUs, 33.33% of which vested on June 1, 2020; 33.33% of which vested on June 1, 2021; with the remaining 33.34% scheduled to vest on June 1, 2022. On August 19, 2021, the Compensation Committee accelerated the vesting of the remaining unvested RSUs.
The number of beneficially owned derivative securities in Column 9 has been adjusted to exclude 10 RSUs that were inadvertently overreported due to clerical error on the Form 4 filed by the reporting person on June 3, 2021. Following the August 19, 2021 vesting of the 72,683 RSUs described in footnote 4, all such RSUs held by the reporting person were fully vested.
The number of beneficially owned derivative securities in Column 9 has been adjusted to exclude 36 RSUs that were inadvertently overreported due to clerical error on the Form 4 filed by the reporting person on June 3, 2021. Following the August 19, 2021 vesting of the 242,277 RSUs described in footnote 5, all such RSUs held by the reporting person were fully vested.
/s/ Carl A. Merton, as Attorney-in-Fact for Irwin D. Simon
2021-08-23